Navigation Links
Cephalon Reported Financial Results for the Second Quarter of 2011
Date:8/2/2011

ge in fair value of investments adjustments

(264,208)

(9)

-Other (income) expense adjustment

16,989

(10)

11,567

(10)Income tax adjustment

39,359

(11)

(38,690)

(11)*Noncontrolling Interest adjustments:Other revenues

-(31)Research and development

1,4176,094Selling, general and administrative1,0633,222Other income (expense)

-166Interest income

-(7)Interest expense

723154Income taxes

-(3,848)Less amount attributable to noncontrolling interest

(3,203)(5,750)(28,267)109,610ADJUSTED NET INCOME ATTRIBUTABLE TO CEPHALON, INC.

$ 300,996$ 309,239BASIC ADJUSTED INCOME PER COMMON SHARE

$
3.95$
4.12DILUTED ADJUSTED INCOME PER COMMON SHARE

$
3.63$
3.81WEIGHTED AVERAGE NUMBER OF COMMONSHARES OUTSTANDING

76,21375,092WEIGHTED AVERAGE NUMBER OF COMMONSHARES OUTSTANDING-ASSUMING DILUTION

82,87181,223* Amounts recorded by our Variable Interest Entities that have been excluded from net income attributable to Cephalon, Inc.Notes to Reconciliation of GAAP Net Income to Adjusted Net Income(1) To exclude the on-going amortization of acquired intangible assets ($56.0M in 2011; $58.0M in 2010), the reversal of a royalty accrual related to AMRIX sales milestones that are no longer expected to be payable ($27.8M in 2011), accelerated depreciation related to restructuring ($10.7M in 2010), amortization of inventory revaluation related to Mepha ($5.0M in 2010) and the write-off of modafinil purchase commitments in excess of estimated requirements ($9.4M in 2010).(2) To exclude accelerated depreciation related to restructuring.(3) In 2011, to exclude charges related to the unsolicited proposal we received from Valeant Pharmaceuticals International and the Agreement and Plan of Merger with Teva Pharmaceutical Industries Ltd. ($20.9M), and charges associated with recent acquisitions.  In 2010, to exclude charges related to t
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Cephalon Quarterly Conference Call Invitation
2. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
3. $425 Million Cephalon Civil Settlement and Criminal Fine; In Americas Largest
4. Cephalon Launches National Consumer Awareness Initiative on Appropriate Use of Prescription Opioid Medications
5. Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules
6. Cephalon Reports Another Strong Quarter
7. Cephalon, Inc. to Webcast Analyst Day
8. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
9. Cephalon Exercises Option to License Worldwide Rights to ImmuPharma Product, Lupuzor
10. Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS
11. Cephalons New Product Launches Pace Record 2008 Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013  Cellular Biomedicine Group (OTCQB: ... enrollment of the total projected enrollment required for ... and preliminary efficacy of the medical technology haMPC ... Osteoarthritis (KOA). To date the trial has had ... The Phase I open label clinical research trial ...
(Date:5/17/2013)... 17, 2013 /PRNewswire-iReach/ -- Aridis is pleased to ... Switzerland -based Kenta Biotech to ... antibody (mAb) products, and technologies. This asset portfolio ... treatment of infections by common pathogens including drug ... Pseudomonas aeruginosa , Acinetobacter baumannii ...
(Date:5/17/2013)... Men’s skin is biologically different than women’s skin,( says ... been known to react more aggressively when hormones change, and ... puberty, other acne causing factors like P.acnes bacteria and excess ... with unsightly acne scars. Adult acne treatment, Probiotic Action shares ... how to reduce and prevent acne scarring. , In order ...
(Date:5/17/2013)... MD (PRWEB) May 17, 2013 ... of ezColony version 4.1, a versatile refinement to ... premier software solution, improves its advanced methodical management ... facilities with ezColony 4.1. The network-based platform provides ... conduct effective research. While continuing to emphasize streamlined ...
Breaking Biology Technology:Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2
... ... and Ralph M. Lerner named Senior Vice President of Commercial Development , ... Marlborough, Mass. (Vocus) October 23, ... technology turns biomass into cellulosic ethanol, has welcomed Kevin F. McLaughlin and Ralph M. ...
... Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ... overview of the Company at the 8th Annual BIO ... 3:00 p.m. PT. The conference will be held at ... and 29, 2009. , A live audio link to ...
... Oct. 23 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... global biopharmaceutical company focused on endocrine therapy and ... previously announced registered direct offering of US$5.5 million ... share purchase warrants to certain institutional investors. AEterna ...
Cached Biology Technology:Cellulosic Biofuels Leader Qteros Adds Key Positions 2Cellulosic Biofuels Leader Qteros Adds Key Positions 3Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009 2AEterna Zentaris Receives US$5.5 Million from Institutional Investors 2AEterna Zentaris Receives US$5.5 Million from Institutional Investors 3
(Date:5/17/2013)... and Sustainable Global Logistics Operations) is aiming to cut ... of intermodal loading systems and the boosting of intelligent ... organisations with experience in the logistics sector and in ... and a duration of three and a half years. ... semantic components and ontologies shared by the users, objects ...
(Date:5/17/2013)... Bethesda, MD The Federation of American Societies for ... of National Institutes of Health (NIH) funding trends highlighting ... to support critical research. The FASEB analysis follows a ... Francis Collins, MD, PhD, who testified that the $1.6 ... to sequestration is "having a substantial impact on the ...
(Date:5/16/2013)... 2013) Illustrating a commitment to the support ... Association (AGA) Research Foundation has announced the inaugural ... Award recipients. Supported by the National Institute of ... new award helps underrepresented minority students to further ... research. , "By establishing this new award, AGA ...
Breaking Biology News(10 mins):New logistics services that will cut energy consumption and CO2 emissions 2Underrepresented minority students receive fellowships in digestive disease and nutrition research 2
... in partnership with Oak Ridge National Laboratory (ORNL) will ... the National Science Foundation (NSF) has deemed the "most ... The two will team up to participate ... continental-scale ecological observatory, to answer questions that deal with ...
... Mass. A six-year campaign to control invasive winter ... Elkinton of the University of Massachusetts Amherst now has ... been established and is attacking the pest at four ... beginning of the end for the decade-long defoliation of ...
... (Santa Barbara, Calif.) Sensors made from custom DNA molecules ... quality of stem cells, according to an international team of ... University of Rome Tor Vergata. The new nanosensors can ... which serve as the master control switches of life. The ...
Cached Biology News:University of Tennessee chosen to join national network to study climate change 2UMass Amherst entomologists begin to control winter moth infestation in eastern Massachusetts 2Nanosensors made from DNA may light path to new cancer tests and drugs 2Nanosensors made from DNA may light path to new cancer tests and drugs 3
Peptide-affinity Purified Polyclonal Antibody to Prolactin Releasing Hormone Receptor (GPR10)...
Peptide-affinity Purified Polyclonal Antibody to Sphingolipid Receptor Edg8/S1P5...
Peptide-affinity Purified Polyclonal Antibody to MAML1 / Mastermind Peptide with sequence VLPTCPMAEFALPR, from N Terminus of the protein sequence according to NP_055572....
DNA sequencing - plasmids or PCR fragments, 3-7 working days service....
Biology Products: